Monoaminergic signaling during mammalian NREM sleep - Recent insights and next-level questions.

Curr Opin Neurobiol

Department of Fundamental Neurosciences, University of Lausanne, Rue du Bugnon 9, 1005 Lausanne, CH, Switzerland. Electronic address:

Published: June 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Subcortical neuromodulatory activity in the mammalian brain enables flexible wake behaviors, which are essential for survival in an ever-changing external environment. With the suppression of such behaviors in sleep, this activity is, on average, much reduced. Recent discoveries, enabled by unprecedented technical advancements, challenge the long-standing view that monoaminergic systems-noradrenaline (NA), dopamine (DA), and serotonin (5-HT)-remain largely inactive during sleep. This review highlights recent technological and scientific progress in this field, summarizing evidence that monoaminergic signaling in the brain supplements sleep with essential wake-related functions. Stress and/or neuropsychiatric conditions negatively impact on monoaminergic signaling, which can lead to sleep disruptions. Furthermore, subcortical neuromodulatory systems are vulnerable to neurodegenerative pathologies, which implies them in sleep disruptions at early stages of disease. We propose that future research will be well-invested in elucidating the spatiotemporal organization, cellular mechanisms, and functional relevance of neuromodulatory dynamics across species, and in identifying the molecular and physiological processes that sustain their integrity throughout the lifespan.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.conb.2025.103025DOI Listing

Publication Analysis

Top Keywords

monoaminergic signaling
12
subcortical neuromodulatory
8
sleep disruptions
8
sleep
6
monoaminergic
4
signaling mammalian
4
mammalian nrem
4
nrem sleep
4
sleep insights
4
insights next-level
4

Similar Publications

Unlabelled: Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BP), significantly impact global health, with MDD affecting over 300 million people and BP affecting approximately 2% of the world's population. Ketamine, originally an anesthetic, has emerged as a promising treatment for patients with treatment-resistant depression (TRD), due to its unique pharmacological properties, such as N-methyl-D-aspartate (NMDA) receptor antagonism and anti-inflammatory effects. The potential of ketamine in treating depression has sparked debate regarding its effects on appetite.

View Article and Find Full Text PDF

When accompanied by excessive exposure to the stressors, pregnancy may result in prenatal depression, that has in turn negative influence on the offspring's brain. Mirtazapine, among other antidepressants, is commonly used to treat prenatal depression. Even though mirtazapine is generally considered safe for pregnant women, its effect on the offspring brain have not been sufficiently investigated.

View Article and Find Full Text PDF

All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants.

Pharmacol Res

August 2025

Goethe University Frankfurt, University Hospital, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, Frankfurt am Main 60596, Germany.

Treatment-resistant depression (TRD) represents a major clinical challenge. Affecting about 30 % of major depressive disorder (MDD) patients, effective treatments for TRD are urgently needed. While depression research and antidepressant (AD) development have long centred on monoaminergic targets, research over the past 35 years has increasingly explored glutamatergic mechanisms.

View Article and Find Full Text PDF

Current commercial antidepressants worldwide are mainly developed according to the monoaminergic hypothesis of depression and have various limitations. Thus, exploring new antidepressants with better therapeutic efficacy and fewer adverse effects remain a hot topic in the field of neuropsychiatric research. Peroxisome proliferator-activated receptors (PPARs) have been demonstrated to closely participate in the pathophysiology of depression, and here we assume that lanifibranor, a novel pan-PPAR agonist for α, δ, and γ, may induce antidepressant-like actions by PPARs activation.

View Article and Find Full Text PDF

Mapping cross-modal functional connectivity of major neurotransmitter systems in the human brain.

Brain Struct Funct

August 2025

Department of Social Psychology and Quantitative Psychology, Institute of Neurosciences, University of Barcelona, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERSAM, Barcelona, Spain.

Monoaminergic systems, including serotonin, dopamine, and norepinephrine, are essential for regulating brain activity and facilitating behavioral flexibility. These systems originate from brainstem nuclei and project widely to modulate functions such as mood, attention, memory, and adaptability. Using resting-state functional MRI (rs-fMRI), this study aimed to investigate the connectivity networks of key monoaminergic nuclei in 193 healthy adults and explore their correspondence with molecular imaging maps of neurotransmitter-specific biochemical markers.

View Article and Find Full Text PDF